Table 4. Multivariate analysis of the effect of biological and clinical features on DFS.
| Parameters | Hazard ratio (95% CI) | P-value |
|---|---|---|
| Insufficient maintenance therapy | 5.60 (2.36–13.26) | <0.001 |
| Age ⩾20 | 1.25 (0.62–2.52) | 0.531 |
| PS ⩾2 | 1.28 (0.42–3.91) | 0.662 |
| CNS involvement (+) | 0.93 (0.19–4.50) | 0.927 |
| WBC ⩾50000 | 1.63 (0.77–3.43) | 0.195 |
| Karyotype high + very high | 0.72 (0.27–1.92) | 0.516 |
| B-cell phenotype | 1.36 (0.58–3.21) | 0.484 |
| Poor PSL response | 1.52 (0.71–3.27) | 0.284 |
| CR by 2nd induction | 1.64 (0.34–7.98) | 0.538 |
| SCT in 1st remission | 1.01 (0.43–2.37) | 0.980 |
Abbreviations: CI, confidence interval; CNS, central nervous system; CR, complete remission; DFS, disease-free survival; PS, performance status; PSL, prednisolone; SCT, stem cell transplantation; WBC, white blood cell.